Efficacy of Ranibizumab Combined with SML in the Treatment of Choroidal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy
Objective:To investigate the effect of Ranibizumab combined with subthreshold micropulse laser(SML)in the treatment of choroidal neovascularization(CNV)secondary to chronic central serous chorioretinopathy(CSC).Method:A total of 68 eyes of CSC patients with secondary CNV in Jingmen Traditional Chinese Medicine Hospital from January 2021 to December 2022 were selected and divided into two groups according to random number table method.34 eyes of 34 patients in the reference group were given intravitreal injection of Ranibizumab.After the first injection,reexamination was conducted once a month to determine whether to be injected with Ranibizumab again according to the change of disease condition.34 eyes of 34 patients in the combination group were treated with SML 2 weeks before Ranibizumab injection therapy(same practice as the reference group).The total number of Ranibizumab injections 12 months after the first Ranibizumab injection in the two groups were counted.Best corrected visual acuity(BCVA),central macular thickness(CMT)levels and retinal blood flow density in macular area were observed before and after 12 months of treatment in the two groups,and the incidence of complications was compared between the two groups.Result:The total number of injections in combination group was significantly lower than that in reference group 12 months after the first injection(P<0.05).The levels of logMAR BCVA and CMT after 12 months of treatment were lower in both groups than those before treatment,and those in combination group were lower than those in reference group(P<0.05).There were no significant differences in blood density of superficial retinal capillary plexus(SCP)and deep retinal capillary plexus(DCP)between the two groups before treatment and 12 months after treatment(P>0.05).There was no significant difference in the incidence of complications between the two groups(P>0.05).Conclusion:Ranibizumab combined with SML can reduce the number of Ranibizumab injection therapy in patients with CSC secondary CNV,help to reduce CMT,and do not affect the retinal blood flow density in macular area,and avoid increasing complications.
RanibizumabSubthreshold micropulse laserChronic central serous chorioretinopathyChoroidal neovascularizationCorrected vision
万方数据
维普
